Nitroheterocyclic derivatives: privileged scaffold for drug development against Chagas disease

Scarim, Caue Benito; Chin, Chung Man

Advanced search

Search - Use quotation marks to get a more specific result

Index

Field of knowledge

Start date

Betweenand

(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Nitroheterocyclic derivatives: privileged scaffold for drug development against Chagas disease

Full text
Author(s):	Scarim, Caue Benito ^[1] ; Chin, Chung Man ^[1] Total Authors: 2
Affiliation:	^[1] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, Km 1 S-N, Campus ville, BR-14800903 Araraquara, SP - Brazil Total Affiliations: 1
Document type:	Review article
Source:	MEDICINAL CHEMISTRY RESEARCH; v. 28, n. 12, p. 2099-2108, DEC 2019.
Web of Science Citations:	0
Abstract
Chagas disease or American trypanosomiasis is a major public health problem in Latin America. Approximately seven million people are currently infected worldwide. Despite the efforts to develop new drugs, only two nitroheterocyclic drugs (nifurtimox and benznidazole) are available for the treatment of Chagas disease, These drugs have been available since the 1970s, and no new drugs have been approved. Due to the lack of alternatives for the treatment of this disease, this review describes recent advances (2013-2019) concerning nitroheterocyclic compounds with activity against T. cruzi parasites, as well as new perspectives for future research. (AU)

FAPESP's process:	16/10847-9 - Hydroxymethylnitrofurazone (NFOH): activity study in chronic phase of Chagas' Disease in an animal model and synthesis of soluble derivatives
Grantee:	Cauê Benito Scarim
Support Opportunities:	Scholarships in Brazil - Doctorate

Short URL